Skip to main content
LYRA logo

Lyra Therapeutics, Inc. (LYRA) Stock Price & Analysis

Lyra Therapeutics, Inc. (LYRA) — price $0.03 (0.00%), as of the Nov 19, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.03 $0.00 (0.00%)

Lyra Therapeutics, Inc. · LYRA

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing anti-inflammatory therapies for chronic rhinosinusitis (CRS).

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • NVO · Novo Nordisk A/S · 87 /100
  • VRTX · Vertex Pharmaceuticals Incorporated · 90 /100
  • REGN · Regeneron Pharmaceuticals, Inc. · 95 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.03
Change on the day0.00%
52-week range$0.0004 – $4.59
Shares traded on the day5.5K

Price & events

Other perspectives

Council score for Lyra Therapeutics (LYRA): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
ROE Negative
Gross Margin Negative

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Lyra Therapeutics (LYRA), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Lyra Therapeutics, Inc. (LYRA) is the company analyzed here. It employs 27 people and is led by Carmichael S. Roberts Jr.. In Q4 FY2025 it reported revenue of $7,000 and net income of -$7M.

2 · Latest results

What do the latest results show for Lyra Therapeutics (LYRA)?

Short answer · as of

The most recent reported quarter, Q4 FY2025, carried revenue of $7,000. Against analyst estimates the company has EPS beat 5 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2025$7,000-$7M-$9.60 (diluted)
Q3 FY2025$25,000-$6M-$3.38 (diluted)
Q2 FY2025$183,000-$7M-$5.51 (diluted)
Q1 FY2025$183,000-$9M-$0.13 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Lyra Therapeutics (LYRA)?

Short answer · as of

The distress and quality screens read Altman Z -19.16 · Piotroski F 3. Trailing ratios: ROE 455.3% · ROA -56.4% · current ratio 1.71.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -19.16 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Lyra Therapeutics (LYRA)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $700,000 · EPS -7.02 · 1 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$700,000
EPS estimate
$-7.02

Measured against a quoted price of $0.03 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
12
Identified insiders
4
Purchases
0
Sales
9
Other transactions
3

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held LYRA in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported LYRA in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About LYRA

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

Is LYRA a good stock to buy?

Stock Expert AI does not rate LYRA buy, sell or hold. Lyra Therapeutics, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the LYRA stock price today?

The last price recorded for Lyra Therapeutics, Inc. (LYRA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key factors to evaluate for LYRA?

Evaluate LYRA on fundamentals, analyst consensus, and risk factors. The company's technology delivers medicines directly to the affected tissue for sustained periods with a single administration. Not financial advice.

How frequently does LYRA data refresh on this page?

LYRA's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven LYRA's recent stock price performance?

Lyra Therapeutics, Inc. (LYRA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug delivery technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider LYRA overvalued or undervalued right now?

Lyra Therapeutics, Inc. (LYRA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research LYRA before investing?

Before investing in Lyra Therapeutics, Inc. (LYRA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding LYRA to a portfolio?

Key strength of Lyra Therapeutics, Inc. (LYRA): Innovative drug delivery technology. Weigh rewards against risks and diversify. Not financial advice.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 8 from Financial Modeling Prep (FMP) and 9 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.